Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
Fisher Biomarker Research Laboratory
robert veltri
Robert W. Veltri, Ph.D.
Associate Professor of Urology
and Oncology
alan partin
Alan W. Partin, MD, PhD
David Hall McConnell Distinguished Professor of Urologic Oncology, Professor and Director of Urology
The Fisher Biorepository Biomarker laboratories are engaged in biomarker research and development to improve the early detection, staging, monitoring, and prognosis of prostate cancer (CaP) and other urologic cancers. A biomarker is a cancer property that can be objectively measured and is an indicator of biological or pathogenic processes, or a patient’s pharmacologic or physiologic responses to a therapeutic intervention.

Robert W. Veltri, Ph.D. is Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine. Currently, Dr. Veltri has DOD grant supported collaborations with Case Western Reserve University biomedical engineering department and they are studying differentiating indolent vs. aggressive prostate cancer (CaP). He NCI grant supported collaborations with PharmaSeq Inc. that develops microtransponder-based (p-Chip) multiplex immunoassays to detect serum or urine biomarkers. He also has a DOD grant to study Cancer Testes Antigens (CTAs) that funds research on identification of aggressive phenotype of CaP : Early Detection Research Network (EDRN) to characterize indolent vs. aggressive CaP (metastatic). Career experiences: 1) Dr. Veltri also served as Professor & Director of Otolaryngic Research and a member of the faculty of microbiology, surgery from 1968-80; 2) He managed R&D at a diagnostic company (1980-84), where he developed rapid FDA approved In Vitro diagnostic devices; 3) In 1985, he co-founded a therapeutics company (Theracel), which created nine patents covering several Aldol and Michael addition derivatives of Vitamin C; 4) at UroCor his R&D team (1991-2001) developed several products including "UroScore", a urinalysis Stones 24-hour product, and a novel bladder cancer molecular-based assay for p53 gene mutations, and the M344 & DD-23 BlCa detection urine biomarker and his R&D group discovered and patented several genes involved in CaP. Dr. Veltri has authored over 10 book chapters and 172 scientific peer reviewed publications and has over twenty patents and two trademarks.

Alan W. Partin, MD, PhD – is  David Hall McConnell Professor and Director of Urology, at Johns Hopkins and has an extensive background spanning twenty years in clinical, laboratory and translational research regarding biomarkers for early detection, staging and monitoring of treatment response for men regarding CaP. Dr. Partin's laboratories and clinical and surgical interest are focused on development and testing of new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. The laboratories have investigated many new serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basics science investigation of new proteins, which may help in detection, and staging of prostate cancer. In addition, Dr. Partin has an academic and clinical interest in treatment of benign prostatic hyperplasia with an emphasis on minimally invasive techniques for treatment of this common disease of men. He has over 600+ publications and holds patents and has been awarded numerous honors for basic and clinical research in the field of urology.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287